Randomized phase II study of eribulin mesylate (E) with or without pembrolizumab (P) for hormone receptor-positive (HR+) metastatic breast cancer (MBC).
暂无分享，去创建一个
E. Winer | L. Trippa | D. Dillon | B. Overmoyer | E. Mittendorf | L. Spring | A. Partridge | Edward T. Richardson | R. Barroso-Sousa | S. Tolaney | I. Krop | G. Wulf | T. Keenan | Jiani Hu | I. Luis | N. Lin | N. Sinclair | C. Andrews | Jessica Pittenger | Eliezer VanAllen | Chelsea Andrews | Laura M. Spring